All posts by admin

11Feb/14

FDA Investigating Heart Failure Risk Linked To Onglyza – Forbes


Drug Discovery & Development

FDA Investigating Heart Failure Risk Linked To Onglyza
Forbes
ureThe FDA said today that it was conducting an investigation of a possible increased risk for heart failure associated with the diabetes drug saxagliptin. Saxagliptin is marketed by AstraZeneca AstraZeneca as Onglyza and Kombiglyze XR. (AstraZeneca …
FDA to Investigate Diabetes Drug Saxagliptin for Possible Heart Failure RiskU.S. News & World Report
FDA to probe saxagliptin’s heart failure riskFamily Practice News Digital Network
FDA Investigating Heart Failure Risks with SaxagliptinDrug Discovery & Development
Healio
all 27 news articles »
11Feb/14

Study: Resilience in parents of children undergoing stem cell transplant – Science Codex

Study: Resilience in parents of children undergoing stem cell transplant
Science Codex
A child’s illness can challenge a parent’s wellbeing. However, a study recently published in the journal Biology of Blood and Marrow Transplantation shows that in the case of a child’s stem cell transplant, parents feel increased distress at the time …
Children’s Medical Center to Host 23rd Annual ‘Be The Match’ Donor Registry …The Herald | HeraldOnline.com (press release)

all 5 news articles »

11Feb/14

Study: Resilience in Parents of Children Undergoing Stem Cell Transplant – Newswise (press release)

Study: Resilience in Parents of Children Undergoing Stem Cell Transplant
Newswise (press release)
Newswise — A child’s illness can challenge a parent’s wellbeing. However, a study recently published in the journal Biology of Blood and Marrow Transplantation shows that in the case of a child’s stem cell transplant, parents feel increased distress …

11Feb/14

Gilead seeks approval for Hepatitis C drug that's innovative — and expensive – San Francisco Chronicle (blog)

Gilead seeks approval for Hepatitis C drug that’s innovative — and expensive
San Francisco Chronicle (blog)
Gilead is also taking heat internationally for its plans to bring Sovaldi to India and other developing countries at a fraction of the U.S. price, about $2,500 for six months of treatment, according to an interview with an Indian pharmaceutical …